AN2 Therapeutics (ANTX) Total Liabilities (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Total Liabilities for 6 consecutive years, with $5.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities fell 28.48% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $5.7 million (down 28.48% YoY), while the FY2025 annual figure was $8.9 million, down 13.17% from the prior year.
• Total Liabilities eased to $5.7 million in Q1 2026 per ANTX's latest filing, from $8.9 million in the prior quarter.
• Across five years, Total Liabilities topped out at $14.8 million in Q3 2023 and bottomed at $4.2 million in Q2 2022.
• Historically, Total Liabilities has averaged $8.6 million across 5 years, with a median of $8.6 million in 2023.
• Annual changes were most pronounced in 2023 — Total Liabilities soared 234.59% — and 2024, when it plunged 32.5%.
• AN2 Therapeutics' Total Liabilities stood at $7.2 million in 2022, then soared by 95.37% to $14.0 million in 2023, then slipped by 27.1% to $10.2 million in 2024, then retreated by 13.17% to $8.9 million in 2025, then plunged by 35.52% to $5.7 million in 2026.
• Business Quant data shows ANTX's Total Liabilities at $5.7 million in Q1 2026, $8.9 million in Q4 2025, and $6.9 million in Q3 2025.